Search results for "FHL1"

showing 4 items of 4 documents

Proteomic identification of FHL1 as the protein mutated in human reducing body myopathy

2007

Reducing body myopathy (RBM) is a rare disorder causing progressive muscular weakness characterized by aggresome-like inclusions in the myofibrils. Identification of genes responsible for RBM by traditional genetic approaches has been impossible due to the frequently sporadic occurrence in affected patients and small family sizes. As an alternative approach to gene identification, we used laser microdissection of intracytoplasmic inclusions identified in patient muscle biopsies, followed by nanoflow liquid chromatography-tandem mass spectrometry and proteomic analysis. The most prominent component of the inclusions was the Xq26.3-encoded four and a half LIM domain 1 (FHL1) protein, expresse…

Models MolecularProteomicsMolecular Sequence DataMuscle ProteinsBiologyTransfectionProteomicsInclusion bodiesMuscular DiseasesmedicineAmino Acid SequenceLaser capture microdissectionInclusion BodiesIntracellular Signaling Peptides and ProteinsCardiac muscleSkeletal muscleGenetic Diseases X-LinkedGeneral MedicineLIM Domain Proteinsmedicine.diseaseCongenital myopathyMolecular biologyFHL1medicine.anatomical_structureMutationMyofibrilResearch Article
researchProduct

G.P.5.10 Novel FHL1 mutation in familial mixed reducing body myopathy with rigid spine

2009

medicine.medical_specialtybusiness.industryRigid spineFHL1Reducing body myopathyEndocrinologyNeurologyInternal medicinePediatrics Perinatology and Child HealthMutation (genetic algorithm)medicineNeurology (clinical)businessGenetics (clinical)Neuromuscular Disorders
researchProduct

Clinical, histological and genetic characterization of reducing body myopathy caused by mutations in FHL1

2008

We recently identified the X-chromosomal four and a half LIM domain gene FHL1 as the causative gene for reducing body myopathy, a disorder characterized by progressive weakness and intracytoplasmic aggregates in muscle that exert reducing activity on menadione nitro-blue-tetrazolium (NBT). The mutations detected in FHL1 affected highly conserved zinc coordinating residues within the second LIM domain and lead to the formation of aggregates when transfected into cells. Our aim was to define the clinical and morphological phenotype of this myopathy and to assess the mutational spectrum of FHL1 mutations in reducing body myopathy in a larger cohort of patients. Patients were ascertained via th…

AdultMaleWeaknessPathologymedicine.medical_specialtyMutation MissenseMuscle ProteinsBiologymedicine.disease_causeMuscular DiseasesBiopsymedicineHumansGenetic Predisposition to DiseaseMyopathyChildMicroscopy ImmunoelectronMuscle SkeletalMutationMuscle biopsymedicine.diagnostic_testIntracellular Signaling Peptides and ProteinsInfantGenetic Diseases X-LinkedOriginal ArticlesLIM Domain Proteinsmedicine.diseaseCongenital myopathyFHL1PedigreeChild PreschoolFemaleNeurology (clinical)medicine.symptomProgressive disease
researchProduct

G.O.2 Proteomic identification of the LIM domain protein FHL1 as the gene-product mutated in reducing body myopathy

2008

Reducing body myopathyGene productNeurologyPediatrics Perinatology and Child HealthIdentification (biology)Neurology (clinical)Computational biologyBiologyGenetics (clinical)FHL1LIM domainNeuromuscular Disorders
researchProduct